Pembrolizumab and Tislelizumab used the Composite Positivity Score (CPS), which assesses PD-L1 expression by dividing the number of PD-L1-positive cells by the total number of tumor cells, and Camrelizumab uses the Tumor Proportion Score (TPS), which assesses PD-L1 expression by the fraction of positive tumor cells, and Tislelizumab uses the Tumor Area Positivity Score (TAP), which assesses PD-L1 expression by the area of PD-L1-stained tumor cells and immune cells as a percentage of the area of all tumors (38). This evidence concerns the gene CD274 and neoplasm.